Compal, together with the Institute for Information Industry and the Industrial Technology Research Institute (ITRI), released the "5G Remote Abdominal Ultrasound Diagnostic Validation Results" on 16 December. Through the construction of a 5G network, technical support feasibility validation and application service introduction, combined with Compal's subsidiary Shennona's remote medical ultrasound image transmission system, Compal has enabled the first 5G remote abdominal ultrasound diagnosis across counties and cities in Taiwan.
Compal pointed out that 5G's low latency, high bandwidth, and wide connectivity allows it to remotely reach out to Jianshi Township in Hsinchu County to conduct abdominal ultrasound examinations for people in the rural areas, significantly advancing the application of telemedicine and mobile medicine, transmitting images in real time, and providing quick medical advice.
The biggest benefit of 5G in ultrasound telemedicine is that the time lag between sensing feedback and command delivery has been reduced, and the sense of delay in manipulation has been reduced, according to Dr. Wei-Yi Fan, director of medical information at Shennona. In the past, long delays caused doctors to think that the remote ultrasound probe had not reached the desired position or that the force applied was too low, thus increasing the distance and force of movement.
Compal's handheld wireless ultrasound products are equipped with patented technology and completely self-developed with the most critical ultrasound probe module, hardware and software system and image processing algorithm, and are much lighter in size.
Compal and ITRI jointly developed 5G small base station low latency transmission technology, which is used in Compal's 5G drone control competition with ITRI, and the technology is applied to smart and precise medical treatment for remote ultrasound detection.
Compal's healthcare footprint continues to grow, and is actively facilitating companies for listing on the stock exchange. In the first half of this year, Compal's Vice Chairman, Mr. Chen Shui Chung, revealed that many of its medical subsidiaries have reached the stage of profitability and will evaluate the operating conditions of individual companies and will not rule out an IPO in the future.
Compal is gradually entering the most central and difficult areas, such as cell therapy, AI medicine and long term care, etc. The Group's medical subsidiaries include Raypal Biomedical, BeneCheck, Avalue Technology and Shennona, etc.
